Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia

被引：11

作者：

Ayatollahi, Hossein ^{[1
]}

Sadeghian, Mohammad Hadi ^{[1
]}

Naderi, Mahmood ^{[2
]}

Jafarian, Amir Hossein ^{[1
]}

Shams, Seyyede Fatemeh ^{[3
,4
]}

Motamedirad, Neda ^{[3
,4
]}

Sheikhi, Maryam ^{[3
,4
]}

Bahrami, Afsane ^{[4
,5
]}

Shakeri, Sepideh ^{[3
,4
]}

机构：

[1] Mashhad Univ Med Sci, Fac Med, Canc Mol Pathol Res Ctr, Dept Hematopathol & Blood Banking, Mashhad, Iran

[2] Univ Tehran Med Sci, Digest Dis Res Inst, Liver & Pancreatobiliary Dis Res Ctr, Tehran, Iran

[3] Mashhad Univ Med Sci, Canc Mol Pathol Res Ctr, Fac Med, Mashhad, Iran

[4] Mashhad Univ Med Sci, Student Res Comm, Fac Med, Mashhad, Iran

[5] Mashhad Univ Med Sci, Sch Med, Dept Modern Sci & Technol, Mashhad, Iran

来源：

JOURNAL OF RESEARCH IN MEDICAL SCIENCES | 2017年 / 22卷

关键词：

Acute myeloid leukemia; minimal residual disease; real-time quantitative polymerase chain reaction; Wilms tumor gene; ACUTE MYELOID-LEUKEMIA; MINIMAL RESIDUAL DISEASE; STEM-CELL TRANSPLANTATION; WT1; GENE-EXPRESSION; MYELODYSPLASTIC SYNDROMES; PERIPHERAL-BLOOD; MARKER; TOOL; PCR;

D O I：

10.4103/jrms.JRMS_448_16

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: The Wilms tumor 1 (WT1) gene is originally defined as a tumor suppressor gene and a transcription factor that overexpressed in leukemic cells. It is highly expressed in more than 80% of acute myeloid leukemia (AML) patients, both in bone marrow (BM) and in peripheral blood (PB), and it is used as a powerful and independent marker of minimal residual disease (MRD); we have determined the expression levels of the WT1 by real-time quantitative polymerase chain reaction (RQ-PCR) in PB and BM in 126 newly diagnosed AML patients. Materials and Methods: This study was done in molecular pathology and cancer research center from April 2014 to June 2015, RQ-PCR method was used to determine the WT1 gene expression in BM and/or PB samples from 126 patients of AML, we cloned both WT1 and ABL genes for creating a standard curve, and we calculate copy number of WT1 genes in patients. Results: A total of 126 AML patients consist of 70 males (55.6%) and 56 females (44.4%), with a median age of 26 years; 104 (81%) patients out of 126 show overexpression of WT1 gene. We also concomitant monitoring of fusion transcripts (PML RARa, AML1-ETO, MLL-MLL, CBFb-MYH11, or DEK-CAN) in our patients, the AML1-ETO group showing remarkably low levels of WT1 compared with other fusion transcript and the CBFB-MYH11 showing high levels of WT1. Conclusion: We conclude that WT1 expression by RQ-PCR in AML patients may be employed as an independent tool to detect MRD in the majority of normal karyotype AML patients.

引用

页数：6

共 19 条

[1] The Level of Bone Marrow WT1 Message is a Useful Marker to Differentiate Myelodysplastic Syndromes with Low Blast Percentage from Cytopenia due to Other Reasons [J].